FeesSafety
Pluang+

Xometry posts record Q3 2026 with 40% revenue growth and improved profitability.

Company Fundamentals
03 Nov 2026, 14:05 WIB
GlobeNewsWire
View Source
Bullish
Xometry posts record Q3 2026 with 40% revenue growth and improved profitability.

Xometry, Inc. reported a record third quarter in 2026, with revenue rising 40% year-over-year to $252 million, driven by strong marketplace growth. Gross profit increased 37% to $98.7 million, and adjusted EBITDA improved significantly to $21.4 million. The company expanded its buyer and supplier networks, enhanced AI-driven marketplace features, and deepened enterprise engagement. For Q4 2026, Xometry expects continued growth with revenue projected between $254-$256 million and adjusted EBITDA of $22-$22.5 million, signaling ongoing operational strength and market expansion.

Xometry's record third quarter results provide context for readers following technology companies. For readers following the Technology sector, here is Pluang's market snapshot as of Nov 03, 2026 19:11 WIB: Out of 150 priced US tech stocks, 76 rose and 73 fell. Notable movers include GPRO at USD 1.01 with a 1-day change of +5.73% and a typical hold time on Pluang of 46 days, AAPL at USD 325.13 down 3.90% with a hold time of 145 days, and MNDY at USD 91.99 down 3.43% with a hold time of 17 days.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
2 hours ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
2 hours ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
2 hours ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
3 hours ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App